Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 11/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172884 | 1.00 | KDM4E (0.54) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172892 | 1.00 | KDM4E (0.54) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172889 | 1.00 | KDM4E (0.54) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172576 | 0.89 | KDM1A (0.60) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172579 | 0.89 | KDM1A (0.60) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172678 | 0.88 | KDM4E (0.55) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL18172681 | 0.88 | KDM4E (0.55) | KDM4EPKMKDM1ATGFBR1STS | |
| SCHEMBL20106808 | 0.87 | KDM1A (0.63) | KDM4EPKMKDM1ASTSGPR119 | |
| SCHEMBL18182295 | 0.83 | KDM1A (0.47) | KDM4EPKMKDM1A | |
| SCHEMBL18172574 | 0.83 | KDM1A (0.58) | KDM4EPKMKDM1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3286172-A1 | LSD1 INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | KDM4E 19/4885PKM 377/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.